Literature DB >> 15149776

The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over.

Heath Kelly1, John Attia, Ross Andrews, Richard F Heller.   

Abstract

The number needed to treat (NNT) and population extensions of the NNT describe the population outcomes of disease treatment, usually for chronic diseases. We have developed similar measures for vaccine preventable diseases based on the number needed to vaccinate. These measures quantify the number of people, or the number of vaccine doses, needed to prevent one event due to disease per year and allow the calculation of the vaccine cost to prevent one event due to disease per year. We used this method to compare influenza and pneumococcal vaccine programmes for people aged 65 years or more. We calculated the vaccine cost (dollars AUD) to prevent a case of disease, a hospitalisation or a death due to influenza or invasive pneumococcal disease each year in this age group. For influenza, the vaccine costs were dollars 598 to prevent one case per year, dollars 10787 per hospitalisation prevented and dollars 74801 per death prevented each year. We assumed all cases of invasive pneumococcal disease were hospitalised so the vaccine cost of dollars 11494 per case prevented was the same as the vaccine cost per hospitalisation prevented, while the vaccine cost per death prevented each year was dollars 49972. These results suggest the vaccine costs for the prevention of one hospitalisation or one death each year due to invasive pneumococcal disease among the elderly in Australia would be similar to the costs for the prevention of one hospitalisation or death due to influenza.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149776     DOI: 10.1016/j.vaccine.2003.11.052

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality.

Authors:  Marc Brisson
Journal:  Can J Public Health       Date:  2008 Sep-Oct

Review 2.  Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review.

Authors:  M R Hoek; H Christensen; W Hellenbrand; P Stefanoff; M Howitz; J M Stuart
Journal:  Epidemiol Infect       Date:  2008-06-18       Impact factor: 2.451

3.  Potential impact of accelerating the primary dose of rotavirus vaccine in infants.

Authors:  Elizabeth E Halvorson; Timothy R Peters; Beverly M Snively; Katherine A Poehling
Journal:  Vaccine       Date:  2012-02-26       Impact factor: 3.641

4.  The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.

Authors:  Jan A C Hontelez; Nico Nagelkerke; Till Bärnighausen; Roel Bakker; Frank Tanser; Marie-Louise Newell; Mark N Lurie; Rob Baltussen; Sake J de Vlas
Journal:  Vaccine       Date:  2011-06-22       Impact factor: 3.641

5.  Number Needed to Quarantine and Proportion of Prevented Infectious Days by Quarantine: Evaluating the Effectiveness of COVID-19 Contact Tracing.

Authors:  Diogo Fernandes da Silva; João Vasco Santos; Filipa Santos Martins
Journal:  Public Health Rep       Date:  2022-08-20       Impact factor: 3.117

6.  Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries.

Authors:  S M A A Evers; A J H A Ament; G L Colombo; H B Konradsen; R R Reinert; D Sauerland; K Wittrup-Jensen; C Loiseau; D S Fedson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

7.  Rotavirus mortality in India: estimates based on a nationally representative survey of diarrhoeal deaths.

Authors:  Shaun K Morris; Shally Awasthi; Ajay Khera; Diego G Bassani; Gagandeep Kang; Umesh D Parashar; Rajesh Kumar; Anita Shet; Roger I Glass; Prabhat Jha
Journal:  Bull World Health Organ       Date:  2012-07-16       Impact factor: 9.408

8.  Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection.

Authors:  Marc Brisson; Nicolas Van de Velde; Philippe De Wals; Marie-Claude Boily
Journal:  CMAJ       Date:  2007-08-20       Impact factor: 8.262

9.  Number needed to immunize to prevent RSV with extended half-life monoclonal antibody.

Authors:  Lyn Finelli; Yoonyoung Choi; Edward Goldstein
Journal:  Vaccine       Date:  2020-06-26       Impact factor: 3.641

10.  Quantifying the impact of community quarantine on SARS transmission in Ontario: estimation of secondary case count difference and number needed to quarantine.

Authors:  Susan J Bondy; Margaret L Russell; Julie Ml Laflèche; Elizabeth Rea
Journal:  BMC Public Health       Date:  2009-12-24       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.